Legend Biotech's CARVYKTI® receives positive CHMP opinion from EMA for expanded label usage in relapsed/refractory multiple myeloma patients.

Legend Biotech's CARVYKTI® has received a positive CHMP opinion from the European Medicines Agency (EMA) for expanded label usage, now covering adult patients with relapsed and refractory multiple myeloma, who have received at least one prior therapy, with disease progression on the last therapy, and are refractory to lenalidomide. The EMA's recommendation will be reviewed by the European Commission for marketing authorization.